secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193125-25-245404
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma discontinues obesity drug TERN-601 after Phase 2 miss; liver enzyme signals seen
--------------------------------------------------------------------------------

- Max placebo-adjusted weight loss 4.6% (p<0.0001) at 500 mg dose; 11.9% discontinued due to AEs.
- Grade 3 liver enzyme elevations in 3 participants post-treatment, 2 deemed drug-related.
- Company will not advance TERN-601 or further invest in metabolic assets.
- Reiterates focus on TERN-701 for CML with clinical data expected this quarter.
- GI AEs most common: nausea 56%, vomiting 26.9%; all mild/moderate and dose-related.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/0001193125-25-245404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/d14463d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer